The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Ongoing clinical development of lapatinib in HER2-positive (HER2+) metastatic breast cancer (MBC): An innovative approach to recruit patients in clinical studies.
S. R. D. Johnston
Consultant or Advisory Role - GlaxoSmithKline
Honoraria - GlaxoSmithKline
Research Funding - GlaxoSmithKline
K. A. Gelmon
Research Funding - GlaxoSmithKline (B)
X. B. Pivot
Consultant or Advisory Role - GlaxoSmithKline; Novartis; Roche; Sanofi
Honoraria - GlaxoSmithKline; Novartis; PharmaMar; Roche; Sanofi
W. J. Gradishar
Consultant or Advisory Role - GlaxoSmithKline
A. Conner
Employment or Leadership Position - GlaxoSmithKline
D. Kothari
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
P. Legenne
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
M. Leigh
Employment or Leadership Position - GlaxoSmithKline
L. O'Rourke
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
R. Parikh
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline